Glucose Bp B. Braun Melsungen

Glucose Bp B. Braun Melsungen is an injectable solution containing glucose monohydrate as the sole active ingredient. It is supplied as a sterile aqueous solution for intravenous administration, with the specific concentration not disclosed in the product label. Marketed in the European Union and available by prescription only, this carbohydrate solution is used as an energy source and fluid component in clinical settings such as parenteral nutrition and hypoglycemia treatment.

Glucose Bp B. Braun Melsungen is employed in several clinical situations where rapid glucose supplementation or fluid replacement is required.

- Treatment of acute hypoglycemia to quickly raise plasma glucose levels. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in perioperative or trauma care. - Support of carbohydrate needs during prolonged fasting or critical illness. - Dilution medium for certain intravenous drug preparations.

Intravenous administration of glucose monohydrate may be associated with a range of physiological responses, most of which are predictable and dose‑related.

Common: - Transient hyperglycemia with elevated blood glucose measurements. - Mild nausea or abdominal discomfort. - Local irritation or redness at the infusion site. - Electrolyte shifts, particularly decreased serum potassium. - Fluid overload in patients with compromised cardiac function. - Headache or dizziness due to rapid osmotic changes.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions such as rash, urticaria, or anaphylaxis. - Hyperosmolar hyperglycemic state in susceptible patients. - Metabolic acidosis associated with extreme hyperglycemia.

When using Glucose Bp B. Braun Melsungen, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Use caution in patients with diabetes mellitus or impaired glucose tolerance. - Monitor fluid balance in individuals with heart failure or renal insufficiency. - Check serum electrolytes, especially potassium and sodium, before and during therapy. - Avoid rapid infusion in neonates and low‑birth‑weight infants. - Consider compatibility with other intravenous solutions to prevent precipitation. - Discontinue if signs of hypersensitivity or severe hyperglycemia develop.

Glucose monohydrate can interact with other medications or solutions administered intravenously, influencing efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin without appropriate glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate. - Concurrent use of diuretics that exacerbate electrolyte disturbances.

Use with caution: - Concurrent administration of potassium‑sparing agents; monitor serum potassium. - Use alongside beta‑blockers in diabetic patients, as they may mask hypoglycemia symptoms. - Combination with other hyperosmolar solutions; observe for fluid overload.